Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years
Terminated · Phase 3 · NCT05513391
Conditions: Influenza Immunization
At a glance
- Research payments reported, 2025
- $81,380
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 366
About the trial
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Tested
- Recombinant influenza vaccine (RIV4) (biological), Quadrivalent influenza vaccine (IIV4) (biological)
- Dates
- Started 2022-11-10; completion 2023-10-03
- Results posted
- Yes
The purpose of this study was to demonstrate the non-inferior HAI immune response of quadrivalent recombinant influenza vaccine (RIV4) vs licensed Egg-Based Quadrivalent Influenza Vaccine (IIV4) for the 4 strains based on the egg-derived antigen in all participants aged 3 to 8 years and to describe the immunogenicity and safety profile of RIV4 compared to IIV4 in participants aged 3 to 8 years.
From ClinicalTrials.gov, last updated 2025-09-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi Pasteur Inc. reported $81,380 in research payments for this study in 2025 (3 payments).
Products named: Flublok Quadrivalent Northern Hemisphere
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Donald M. Brandon, M.D. Internal Medicine · San Diego, CA
- Peter E. Silas, M.D. Pediatrics · Syracuse, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Alliance for Multispecialty Research,llc $80,743
- California Research Foundation $637
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.